Trials / Completed
CompletedNCT03941808
Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.
Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The role of the oxidative stress in vitiligo is supported by many studies but robust data are lacking concerning their interest as therapeutic agents. The objective of the study is to compare the association of GLISODIN (a gastro-protected superoxide dismutase) and Nb-UVB to Nb-UVB and placebo for treating vitiligo. Adult patients with non-segmental vitiligo affecting more than 5% of body surface area will be included. The main criteria of evaluation will be the VES score at 6 months compared to baseline in both groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glisodin tablet | 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months |
| DRUG | Placebo tablet | 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months |
Timeline
- Start date
- 2019-06-17
- Primary completion
- 2020-05-02
- Completion
- 2020-12-01
- First posted
- 2019-05-08
- Last updated
- 2026-03-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03941808. Inclusion in this directory is not an endorsement.